Leena Tiainen1, Mari Hämäläinen2, Tiina Luukkaala3, Minna Tanner4, Outi Lahdenperä5, Pia Vihinen5, Arja Jukkola4, Peeter Karihtala6, Eeva Moilanen2, Pirkko-Liisa Kellokumpu-Lehtinen4. 1. Department of Oncology, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland; Department of Oncology, Tampere University Hospital, Tampere, Finland. Electronic address: leena.tiainen@tuni.fi. 2. The Immunopharmacology Research Group, Faculty of Medicine and Health Technology, Tampere University and Tampere University Hospital, Tampere, Finland. 3. Research, Development and Innovation Center, Tampere University Hospital and Health Sciences, Faculty of Social Sciences, Tampere University, Tampere, Finland. 4. Department of Oncology, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland; Department of Oncology, Tampere University Hospital, Tampere, Finland. 5. Department of Oncology and Radiotherapy and FICAN West Cancer Center, Turku University Central Hospital, Turku, Finland. 6. Department of Oncology and Radiotherapy, Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland.
Abstract
BACKGROUND: Interleukin (IL)-8 is a proinflammatory cytokine, and high levels of IL-8 are associated with poor prognosis in many malignancies. The objective of this study was to explore the clinical benefit of monitoring plasma IL-8 levels during breast cancer chemotherapy. PATIENTS AND METHODS: We conducted an exploratory analysis of several circulating proteins, including IL-8, in the plasma. Plasma samples were obtained from 58 metastatic breast cancer patients who took part in a prospective phase 2 first-line bevacizumab chemotherapy trial. Samples were analyzed before therapy, after 6 weeks and 6 months of treatment, and at the final study visit. On the basis of a trajectory analysis of the plasma IL-8 levels, the patients were divided into 3 trajectory groups. RESULTS: Plasma IL-8, IL-6, IL-18, matrix metalloproteinase (MMP)-2, MMP-9, YKL-40, resistin, and high-mobility group box 1 (HMGB1) concentrations were measured, and the most pronounced predictor of patient survival was IL-8. On the basis of the trajectory analysis of the IL-8 levels, the majority of patients (n = 35, 60%) belonged to trajectory group 1, and these patients had significantly lower IL-8 levels before and during the entire chemotherapy treatment period than did the patients in the other groups. Trajectory group 1 patients had significantly better overall survival compared to patients in trajectory group 2 (n = 17; age-adjusted HR = 2.45; 95% confidence interval, 1.21-5.97; P = .012) and 3 (n = 6; age-adjusted HR = 8.65; 95% confidence interval, 3.16-23.7; P < .001). CONCLUSION: Low IL-8 levels during chemotherapy treatment might help identify patients with prolonged survival.
BACKGROUND:Interleukin (IL)-8 is a proinflammatory cytokine, and high levels of IL-8 are associated with poor prognosis in many malignancies. The objective of this study was to explore the clinical benefit of monitoring plasma IL-8 levels during breast cancer chemotherapy. PATIENTS AND METHODS: We conducted an exploratory analysis of several circulating proteins, including IL-8, in the plasma. Plasma samples were obtained from 58 metastatic breast cancerpatients who took part in a prospective phase 2 first-line bevacizumab chemotherapy trial. Samples were analyzed before therapy, after 6 weeks and 6 months of treatment, and at the final study visit. On the basis of a trajectory analysis of the plasma IL-8 levels, the patients were divided into 3 trajectory groups. RESULTS: Plasma IL-8, IL-6, IL-18, matrix metalloproteinase (MMP)-2, MMP-9, YKL-40, resistin, and high-mobility group box 1 (HMGB1) concentrations were measured, and the most pronounced predictor of patient survival was IL-8. On the basis of the trajectory analysis of the IL-8 levels, the majority of patients (n = 35, 60%) belonged to trajectory group 1, and these patients had significantly lower IL-8 levels before and during the entire chemotherapy treatment period than did the patients in the other groups. Trajectory group 1 patients had significantly better overall survival compared to patients in trajectory group 2 (n = 17; age-adjusted HR = 2.45; 95% confidence interval, 1.21-5.97; P = .012) and 3 (n = 6; age-adjusted HR = 8.65; 95% confidence interval, 3.16-23.7; P < .001). CONCLUSION: Low IL-8 levels during chemotherapy treatment might help identify patients with prolonged survival.
Authors: Tim Schauer; Anna Henriksson; Emelie Strandberg; Henrik Lindman; Sveinung Berntsen; Ingrid Demmelmaier; Truls Raastad; Karin Nordin; Jesper F Christensen Journal: Int J Clin Oncol Date: 2022-10-21 Impact factor: 3.850
Authors: Bernardo L Rapoport; Helen C Steel; Annette J Theron; Liezl Heyman; Teresa Smit; Yastira Ramdas; Ronald Anderson Journal: Cells Date: 2020-07-10 Impact factor: 6.600
Authors: David B Bartlett; Erik D Hanson; Jordan T Lee; Chad W Wagoner; Elizabeth P Harrell; Stephanie A Sullivan; Lauren C Bates; Mohamdod S Alzer; Dean J Amatuli; Allison M Deal; Brian C Jensen; Grace MacDonald; Michael A Deal; Hyman B Muss; Kirsten A Nyrop; Claudio L Battaglini Journal: Front Immunol Date: 2021-10-27 Impact factor: 7.561